Status:
COMPLETED
Optimization of MDA With Existing Drug Regimens for LF: Monitoring Efficacy of Ongoing Treatment Programs in PNG
Lead Sponsor:
University Hospitals Cleveland Medical Center
Collaborating Sponsors:
Papua New Guinea Institute of Medical Research
Conditions:
Lymphatic Filariasis
Eligibility:
All Genders
5+ years
Brief Summary
The standard regimen for elimination of lymphatic filariasis (LF) in PNG is annual administration of two drugs at the same time. The two drugs are called "DEC" (Diethylcarbamazine, 6 mg/kg body weight...
Detailed Description
This research will conduct a population-based field studies to determine whether the relative cost and efficacy of semi-annual versus annual administration of MDA using DEC (6 mg/kg body weight) plus ...
Eligibility Criteria
Inclusion
- Individuals aged \>=5 years of age in the community
- Willingness to give informed consent to participate in the study
- Willingness of parents or guardians to give consent for minors to participate in study
Exclusion
- 1\. Not willing or able to give informed consent for the study
Key Trial Info
Start Date :
June 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2018
Estimated Enrollment :
3200 Patients enrolled
Trial Details
Trial ID
NCT03268252
Start Date
June 1 2012
End Date
December 1 2018
Last Update
April 26 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Papua New Guinean Institute for Medical Research
Maprik, Sandaun Province, Papua New Guinea